Showing 1216 Results
Value Depends on Real-World Evidence
In his latest commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard examines the challenges with developing, analyzing, using and communicating real-world evidence in…
An Important Dialogue About Orphan Drugs
While it’s encouraging to see that the Institute for Clinical and Economic Review (ICER) began the conversation about the value of orphan drugs, treatments that are used for conditions affecting very…
Checking In With Schaeffer-NPC Postdoctoral Fellow in Health Policy, Dr. Ilene Hollin
Ilene Hollin, PhD, is entering the second year of her NPC-USC Schaeffer Center Health Policy fellowship, a post-doctoral, two-year fellowship that seeks to bridge the gap between health research and…
An Opportunity to Thoughtfully and Holistically Address Health Care Spending
The Medicare Trustees Annual Report issued last week was a mix of positive news and a stark reminder that we need to find thoughtful solutions to ensure that the Medicare program will remain solvent…
Same Condition, Different Costs: Should Patients Pay Different Amounts?
Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Join NPC in tackling this dilemma in the…
Will Value Assessment Frameworks Promote Health Value and Access for Veterans?
NPC expressed concerns about the partnership between the Institute for Clinical and Economic Review and the U.S. Department of Veterans Affairs Pharmacy Benefits Management Services office to…
CER Collaborative Helps Health Care Decision-Makers Assess Evidence
A feature article in this month's Value and Outcomes Spotlight highlights the importance of comparative effectiveness research (CER) and details the CER Collaborative Initiative, a joint effort by…
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
NPC Evaluates ICER’s Revised Value Assessment Framework
The Institute for Clinical and Economic Review (ICER) today released its revised value assessment framework, which included a number of changes reflected in NPC's extensive public comments, but NPC…
NPC @ AcademyHealth Annual Research Meeting: What Do We Know about High-Deductible Health Plans?
NCP Health Policy Fellow Ilene L. Hollin, PhD, MPH, will moderate a panel, “What Do We Know about High-Deductible Health Plans and What Do We Need to Learn?” to discuss what we know – and don’t know …
Driving Innovation Via All Health Care Sectors
Patients are often living longer and experiencing a better quality of life thanks to medical innovation. Biopharmaceutical companies are helping to lead the charge, but other stakeholders have an…
NPC @ DIA 2017 Annual Meeting: Exploring Comparative Effectiveness Research
NPC Chief Science Officer and Executive Vice President Robert Dubois, MD, PhD, will address how comparative effectiveness research is being used by health care decision-makers at the Drug Information…
Asking the Right Questions About Our Health Care System Costs
With health news headlines focused on drug prices, the Senate Committee on Health, Education, Labor and Pensions is holding a hearing today titled, "The Cost of Prescription Drugs: How the Drug…
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…
Optimization of Medication Use at Accountable Care Organizations
This study assesses a broad range of factors related to how accountable care organizations optimize medication use and meet financial and quality metrics.
Why Value Framework Assessments Arrive at Different Conclusions
New peer-reviewed research from the National Pharmaceutical Council (NPC) found inconsistencies in how four value frameworks assessed multiple myeloma treatments.
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.